Skip to NavigationSkip to content

Pfizer recall two batches of migraine drug Relpax

Published on 16/08/19 at 08:20am

Pfizer has recalled two lots of its migraine drug Relpax over concerns about microbiological contamination.

In a statement on the FDA website, Pfizer said: “Individuals who consume oral products contaminated with microorganisms are at risk of bacterial dissemination from the gut to the bloodstream potentially resulting in serious, life- threatening infections.”

However the firm said the risk of infection was low for the general population. The risk may be higher for those with compromised immune systems, cystic fibrosis and chronic granulomatous disease.

The two lots of 40mg tablets are labelled AR5407 and CD4565. Pfizer has not yet received any complaints or reports of adverse events relating to the batches.

Louis Goss

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches